These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 5093250)

  • 21. [Stability and stabilization of drugs. I. Introduction].
    Büchi J
    Pharm Acta Helv; 1967 May; 42(5):257-64. PubMed ID: 5613123
    [No Abstract]   [Full Text] [Related]  

  • 22. An evaluation of Phenonip as a preservative.
    Lucas JE; McCarthy TJ
    Acta Pharm Suec; 1970 Apr; 7(2):149-55. PubMed ID: 4912124
    [No Abstract]   [Full Text] [Related]  

  • 23. Biological indicator comparative analysis in various product formulations and closure sites.
    Berger TJ; Chavez C; Tew RD; Navasca FT; Ostrow DH
    PDA J Pharm Sci Technol; 2000; 54(2):101-9. PubMed ID: 10822980
    [No Abstract]   [Full Text] [Related]  

  • 24. The inclusion of antimicrobial agents in pharmaceutical products.
    Russell AD; Jenkins J; Harrison IH
    Adv Appl Microbiol; 1967; 9():1-38. PubMed ID: 4866750
    [No Abstract]   [Full Text] [Related]  

  • 25. Pharmaceutical development, quality control, stability and compatibility of a parenteral lyophilized formulation of the investigational polymer-conjugated platinum antineoplastic agent AP5346.
    Van der Schoot SC; Nuijen B; Sood P; Thurmond KB; Stewart DR; Rice JR; Beijnen JH
    Pharmazie; 2006 Oct; 61(10):835-44. PubMed ID: 17069422
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Process simulation testing for aseptically filled products. Parenteral Drug Association.
    PDA J Pharm Sci Technol; 1996; 50 Suppl 1():S1-16. PubMed ID: 9038088
    [No Abstract]   [Full Text] [Related]  

  • 27. [Development of formulation of hipromellose eye drops (artificial tears)].
    Inkeniene AM; Klimas R; Briedis V; Maciulevicius J
    Medicina (Kaunas); 2003; 39(1):77-82. PubMed ID: 12576769
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Pharmaceutic aids, their importance and classification].
    Melichar M; Chalabala M
    Cesk Farm; 1973 Mar; 22(2):82-8. PubMed ID: 4571588
    [No Abstract]   [Full Text] [Related]  

  • 29. [Microbiologic purity of drugs. Directions and methods for a pharmacopoeia].
    Bühlmann X; Gay M; Gubler HU; Hess H; Kabay A; Knüsel F; Sackmann W; Schiller I; Urban S
    Pharm Acta Helv; 1971 Jun; 46(6):321-50. PubMed ID: 4934777
    [No Abstract]   [Full Text] [Related]  

  • 30. [On the stability and time of suitability of chemical-pharmaceutical preparations and ready-made drug forms].
    Iaskina DZ; Mishin VP; Gritsenko SV
    Farmatsiia; 1968; 17(1):81-6. PubMed ID: 4885469
    [No Abstract]   [Full Text] [Related]  

  • 31. [Effects of thermal and radiation sterilization on the behavior of some synthetic dyes used in Poland for dyeing of pharmaceutical preparations].
    Wójcik Z; Szyszko E; Zagórski Z
    Acta Pol Pharm; 1973 Oct; 30(5):519-26. PubMed ID: 4764193
    [No Abstract]   [Full Text] [Related]  

  • 32. [Problems of control of polymers used in drug technology].
    Krówczyński L
    Polim Med; 1984; 14(1-4):5-12. PubMed ID: 6533635
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Some galenic procedures used in the substitution therapy with Lactobacillus acidophilus].
    Gumma A; Mirimanoff A
    Pharm Acta Helv; 1971 May; 46(5):278-89. PubMed ID: 4997965
    [No Abstract]   [Full Text] [Related]  

  • 34. [Mechanism of action of burst substances in tablets].
    Hüttenrauch R; Jacob J
    Pharmazie; 1971 May; 26(5):293-8. PubMed ID: 5563062
    [No Abstract]   [Full Text] [Related]  

  • 35. [Industrial production of suppositories].
    Poulet MM
    Farmaco Prat; 1968 Sep; 23(9):447-61. PubMed ID: 5721243
    [No Abstract]   [Full Text] [Related]  

  • 36. Formulation of Neulasta (pegfilgrastim).
    Piedmonte DM; Treuheit MJ
    Adv Drug Deliv Rev; 2008 Jan; 60(1):50-8. PubMed ID: 17822802
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Technical and present therapeutic aspects of tablet manufacture].
    Jaminet F
    Pharm Acta Helv; 1968 Mar; 43(3):129-52. PubMed ID: 4888486
    [No Abstract]   [Full Text] [Related]  

  • 38. The adsorption of preservatives on membrane filters.
    Van Ooteghem M; Herbots H
    Pharm Acta Helv; 1969 Oct; 44(10):602-10. PubMed ID: 5354571
    [No Abstract]   [Full Text] [Related]  

  • 39. Formulation design and development of parenteral suspensions.
    Akers MJ; Fites AL; Robison RL
    J Parenter Sci Technol; 1987; 41(3):88-96. PubMed ID: 3612415
    [No Abstract]   [Full Text] [Related]  

  • 40. [Eye ointments as a drug form].
    Brenner J
    Pharm Acta Helv; 1969 Apr; 44(4):198-207. PubMed ID: 4891841
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.